A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies

NCT02354417 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies

Interventions

BIOLOGICAL: Biological: ProHema-CB

Sponsor

Fate Therapeutics